BRAINSTORM CELL THERAPEUTICS's ticker is BCLI and the CUSIP is 10501E201. A total of 59 filers reported holding BRAINSTORM CELL THERAPEUTICS in Q3 2023. The put-call ratio across all filers is 0.29 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,996 | -86.5% | 14,978 | +39.5% | 0.00% | – |
| Q2 2023 | $22,122 | -38.6% | 10,739 | -1.8% | 0.00% | – |
| Q1 2023 | $36,008 | +125.0% | 10,939 | -0.9% | 0.00% | – |
| Q4 2022 | $16,000 | -66.7% | 11,039 | +1.8% | 0.00% | – |
| Q3 2022 | $48,000 | +54.8% | 10,839 | 0.0% | 0.00% | – |
| Q2 2022 | $31,000 | -97.7% | 10,839 | 0.0% | 0.00% | -100.0% |
| Q1 2022 | $1,329,000 | +3222.5% | 10,839 | +7.1% | 0.00% | – |
| Q4 2021 | $40,000 | +8.1% | 10,120 | -7.3% | 0.00% | – |
| Q3 2021 | $37,000 | -11.9% | 10,920 | 0.0% | 0.00% | – |
| Q2 2021 | $42,000 | -54.3% | 10,920 | -54.5% | 0.00% | – |
| Q1 2021 | $92,000 | -7.1% | 23,981 | +10.2% | 0.00% | – |
| Q4 2020 | $99,000 | -89.6% | 21,761 | -61.2% | 0.00% | -100.0% |
| Q3 2020 | $948,000 | +989.7% | 56,104 | +619.3% | 0.00% | – |
| Q2 2020 | $87,000 | +117.5% | 7,800 | -8.2% | 0.00% | – |
| Q1 2020 | $40,000 | – | 8,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Weaver Consulting Group | 130,000 | $437,000 | 0.21% |
| Ikarian Capital, LLC | 304,161 | $1,022,000 | 0.13% |
| ABNER HERRMAN & BROCK LLC | 265,000 | $890,000 | 0.12% |
| S.C. Financial Services, Inc. | 15,285 | $51,000 | 0.06% |
| JMAC ENTERPRISES LLC | 45,430 | $153,000 | 0.04% |
| CFO4Life Group, LLC | 12,000 | $40,000 | 0.01% |
| OSAIC HOLDINGS, INC. | 10,839 | $1,329,000 | 0.00% |
| INSTITUTIONAL & FAMILY ASSET MANAGEMENT, LLC | 3,000 | $10,000 | 0.00% |
| BOOTHBAY FUND MANAGEMENT, LLC | 29,186 | $98,000 | 0.00% |
| RAYMOND JAMES & ASSOCIATES | 190,403 | $640,000 | 0.00% |